Opthea Joins the S&P/ASX 300 Index
23 sept. 2024 07h00 HE
|
Opthea Limited
MELBOURNE, Australia and PRINCETON, N.J., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel...
Opthea Announces Completion of Drug Substance PPQ Campaign Validating Manufacturing Process of Sozinibercept
18 sept. 2024 07h30 HE
|
Opthea Limited
Three consecutive commercial-scale batches successfully produced Major milestone for potential BLA filing of sozinibercept in wet AMD Progress update of drug product PPQ campaign expected in...
Opthea to Have Significant Presence at the 24ᵗʰ EURETINA Congress and EURETINA Innovation Spotlight
10 sept. 2024 07h30 HE
|
Opthea Limited
MELBOURNE, Australia and PRINCETON, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel...
Opthea Announces Executive Leadership Changes and Senior Hires
05 sept. 2024 06h00 HE
|
Opthea Limited
Daniel Geffken and Mike Campbell respectively appointed CFO ad interim and CCOThree senior leaders appointed for Biometrics, Clinical Operations and Market AccessDeepening retina and launch expertise...
Opthea to Participate in H.C. Wainwright 26th Global Investment Conference and Cantor 2024 Global Healthcare Conference
03 sept. 2024 07h30 HE
|
Opthea Limited
MELBOURNE, Australia and PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel...
Opthea Reports Full-Year Financial Results and Business Updates
30 août 2024 07h30 HE
|
Opthea Limited
Completed patient enrollment in COAST and ShORe pivotal wet AMD trials Financings extended cash runway through topline data readout of both trials in CY2025 Leadership appointments in...
Opthea to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, August 15, 2024
08 août 2024 08h10 HE
|
Opthea Limited
MELBOURNE, Australia and PRINCETON, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel...
Opthea Welcomes International Retina Thought Leaders to Join Its Medical Advisory Board
17 juil. 2024 07h15 HE
|
Opthea Limited
MELBOURNE, Australia and PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel...
Opthea Announces Results of the A$55.9m (US$36.9m¹) Retail Entitlement Offer
14 juil. 2024 21h46 HE
|
Opthea Limited
New Shares under the Retail Entitlement Offer and New Options under the Placement and Entitlement Offer expected to commence normal trading on Thursday, 18 July 2024 Retail Entitlement Offer follows...
Opthea Announces Publication on VEGF-C and D Signaling Pathways as Potential Targets for Treatment of Wet AMD
09 juil. 2024 07h30 HE
|
Opthea Limited
Research underpins sozinibercept’s potential as novel, first-in-class VEGF-C/D ‘trap’ to prevent blood vessel growth and vascular leakage in the retina Published in peer-reviewed journal...